Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sonja Badovinac is active.

Publication


Featured researches published by Sonja Badovinac.


Jornal Brasileiro De Pneumologia | 2013

Stress cardiomyopathy following acute ischemic stroke during flexible bronchoscopy: a rare sequence of complications

Sonja Badovinac; Marta Korsic; Branka Čučević; Valentina Slivnjak; Andrea Vukic Dugac; Marko Jakopovic

To the Editor: Flexible bronchoscopy is a routine procedure used in a wide spectrum of airway pathologies, with a rare incidence of severe complications. We would like to present a case of a rare and odd sequence of complications in a patient treated in our clinic. A 74-year-old woman who had metastatic angiosarcoma in the thoracic wall, with known multiple pulmonary metastases, previously treated with chemotherapy, and without medical history of vascular diseases was admitted to our clinic due to hemoptysis and fever. At admission, the neurological status of the patient was unremarkable, and the patient showed no signs of chest pain. Baseline electrocardiogram (ECG) revealed


Wiener Klinische Wochenschrift | 2015

Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study

Marta Korsic; Sonja Badovinac; Branka Čučević; Zoran Janevski

SummaryAimThe aim of this study is to investigate whether there was a considerable difference in the survival of patients with malignant pleural effusion (MPE) depending on the pleural effusion treatment option.MethodsOne hundred and seven patients with proven MPE (metastatic lung and breast cancer) were included in the retrospective study. Fifty six patients were treated with talc pleurodesis and a control group of 51 patients with similar characteristics (in age, sex and disease) were treated with serial thoracentesis. The patients of both groups underwent chemotherapy and/or radiotherapy. The overall survival and the survival in subgroups of patients with different tumour types and different performance status (PS) equal 1, 2 and 3 were compared.ResultsThe patients who underwent talc pleurodesis had a longer average survival interval (MS) than the patients without such a treatment (n = 56; MS = 21,5 and n = 51; MS = 9 weeks, respectively; p < 0.001). The best results were achieved in patients with PS 1 (n = 16; MS = 35.5 and n = 10; MS = 11 weeks in the groups with and without talc pleurodesis, respectively; p < 0,001) and PS 2 (n = 27; MS = 21 and n = 30; MS = 10 weeks in the groups with and without talc pleurodesis, respectively; p < 0.001), whereas talc pleurodesis was not effective in PS 3 patients (n = 13; MS = 10 and n = 11; MS = 7 weeks in the groups with and without talc pleurodesis, respectively; p = 0.08). Patients with the breast cancer showed a longer average survival interval after pleurodesis than those with the lung cancer (n = 12; MS = 37.5 and n = 44; MS = 20 weeks in the group with the breast cancer and with the lung cancer, respectively; p < 0.001), whereas the median survival was not significantly different between those patients without pleurodesis (n = 10; MS = 10 and n = 41; MS = 9 weeks in the group with the breast cancer and lung cancer, respectively; p = 0.11).ConclusionThe patients treated with talc pleurodesis had a significantly longer average survival than the patients without such a treatment, especially in the group with the breast cancer and in groups with better performance status. This may indicate that talc pleurodesis, apart from its symptomatic effect on the cessation of pleural effusion, may have a direct antitumour effect as well.


Journal of Thoracic Disease | 2016

Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer

Sonja Badovinac; Marta Korsic; Davorka Mursic; Miroslav Samarzija; Branka Čučević; Mihovil Roglić; Marko Jakopovic

BACKGROUND Lung cancer is the leading cause of cancer deaths and the non-small cell lung cancer (NSCLC) represents 80% of all cases. In most cases when diagnosed, it is in locally advanced or metastatic stage, when platinum based doublet chemotherapy is the established therapeutic option for majority of the patients. Predictive factors to filter the patients who will benefit the most from the chemotherapy are not clearly defined. Objective of this study was to explore predictive value of pre-treatment C-reactive protein (CRP), fibrinogen and their interaction, for the response to the frontline chemotherapy. METHODS In this retrospective cohort study 170 patients with locally advanced and metastatic NSCLC were included. Relationship between baseline level of CRP and fibrinogen and response to the frontline chemotherapy was assessed. RESULTS We found that pre-treatment CRP and fibrinogen values were statistically significantly correlated. Chemotherapy and CRP, fibrinogen, and their interaction were independently significantly associated with disease control rate at re-evaluation. There was statistically significant difference in median pre-treatment CRP level between the patients with disease control or progression at re-evaluation, 13.8 vs. 30.0 mg/L respectively, P=0.026. By Johnson-Neyman technique we found that in patients with initial fibrinogen value below 3.5 g/L, CRP level was significantly associated with disease control or progression of the disease. Above this fibrinogen value the association of CRP and disease control was lost. CONCLUSIONS The findings from this study support the growing evidence of inflammation and cancer relationship, where elevated pre-treatment level of CRP has negative predictive significance on the NSCLC frontline chemotherapy response.


European Respiratory Journal | 2017

Coexistence of chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer and impact on survival

Davorka Mursic; Sonja Badovinac; Marta Korsic; Filip Popovic; Mihovil Roglić; Branka Čučević; Marko Jakopovic; Miroslav Samarzija


European Respiratory Journal | 2017

Thymic neoplasms: clinical presentation, diagnosis and management - A single institution experience

Davorka Mursic; Sonja Badovinac; Marta Korsic; Filip Popovic; Mihovil Roglić; Branka Čučević; Marko Jakopovic; Miroslav Samarzija


Thorax 2014 : 4. Kongres Hrvatskog torakalnog društva s međunarodnim sudjelovanjem = 4th Congress of the Croatian Thoracic Society with international participation, Zagreb, 4. – 7. 6 2014, Zagreb | 2014

Endothelial dysfunction and systemic inflammation during acute exacerbations of COPD

Andrea Vukic Dugac; Sanja Popović-Grle; Blaženka Barišić; Tajana Jalušić-Glunčić; Bojana Butorac Petanjek; Sonja Badovinac; Ljerka Glad; Alen Ružić; Samaržija, Miroslav, Jakopović, Marko


Medix : specijalizirani medicinski dvomjesečnik | 2014

Liječenje kronične opstruktivne plućne bolesti

Marta Korsic; Sonja Badovinac; Mihovil Roglić; Branka Čučević


Medix : specijalizirani medicinski dvomjesečnik | 2014

Ciljana terapija karcinoma pluća

Sonja Badovinac; Marta Korsic; Branka Čučević; Mihovil Roglić; Marko Jakopovic; Miroslav Samaržija


Medix : specijalizirani medicinski dvomjesečnik | 2014

Targeted therapy of lung cancer

Sonja Badovinac; Marta Korsic; Branka Čučević; Mihovil Roglić; Marko Jakopovic; Miroslav Samaržija


Medix : specijalizirani medicinski dvomjesečnik | 2014

Therapy of chronic obstructive pulmonary disease

Marta Korsic; Sonja Badovinac; Mihovil Roglić; Branka Čučević

Collaboration


Dive into the Sonja Badovinac's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mihovil Roglić

University Hospital Centre Zagreb

View shared research outputs
Top Co-Authors

Avatar

Davorka Mursic

University Hospital Centre Zagreb

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Filip Popovic

University Hospital Centre Zagreb

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sanja Popović-Grle

University Hospital Centre Zagreb

View shared research outputs
Researchain Logo
Decentralizing Knowledge